EA202090266A1 - Ингибиторы mpo для применения в медицине - Google Patents

Ингибиторы mpo для применения в медицине

Info

Publication number
EA202090266A1
EA202090266A1 EA202090266A EA202090266A EA202090266A1 EA 202090266 A1 EA202090266 A1 EA 202090266A1 EA 202090266 A EA202090266 A EA 202090266A EA 202090266 A EA202090266 A EA 202090266A EA 202090266 A1 EA202090266 A1 EA 202090266A1
Authority
EA
Eurasian Patent Office
Prior art keywords
medical use
mpo inhibitors
mpo
inhibitors
methods
Prior art date
Application number
EA202090266A
Other languages
English (en)
Inventor
Эндрю Уиттакер
Хитеш Джаянтилал Сангани
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA202090266A1 publication Critical patent/EA202090266A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Abstract

Настоящее изобретение относится к новым терапевтическим путям применения ингибиторов МРО и способам лечения, предусматривающим их использование.
EA202090266A 2017-07-17 2018-07-12 Ингибиторы mpo для применения в медицине EA202090266A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762533448P 2017-07-17 2017-07-17
PCT/EP2018/068992 WO2019016074A1 (en) 2017-07-17 2018-07-12 DFO INHIBITORS FOR USE IN MEDICINE

Publications (1)

Publication Number Publication Date
EA202090266A1 true EA202090266A1 (ru) 2020-06-05

Family

ID=62904484

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090266A EA202090266A1 (ru) 2017-07-17 2018-07-12 Ингибиторы mpo для применения в медицине

Country Status (15)

Country Link
US (2) US11246870B2 (ru)
EP (1) EP3654983B1 (ru)
JP (1) JP7220193B2 (ru)
KR (1) KR20200029513A (ru)
CN (1) CN110891572B (ru)
AU (1) AU2018304508B2 (ru)
BR (1) BR112019026270A2 (ru)
CA (1) CA3068910A1 (ru)
EA (1) EA202090266A1 (ru)
ES (1) ES2963315T3 (ru)
IL (1) IL272043B (ru)
MA (1) MA49618A (ru)
SG (1) SG11202000086PA (ru)
WO (1) WO2019016074A1 (ru)
ZA (1) ZA202000904B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49618A (fr) 2017-07-17 2020-05-27 Astrazeneca Ab Inhibiteurs de la mpo destinés à être utilisés en médecine
US20240067651A1 (en) * 2019-10-10 2024-02-29 Biohaven Therapeutics Ltd. Prodrugs of myeloperoxidase inhibitors
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2362101A (en) 2000-05-12 2001-11-14 Astrazeneca Ab Treatment of chronic obstructive pulmonary disease
SE0201193D0 (sv) * 2002-04-19 2002-04-19 Astrazeneca Ab Novel use
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
CN101282762A (zh) 2005-07-05 2008-10-08 生产力技术控股有限公司 改善妊娠结局的方法和组合物
AR066936A1 (es) 2007-06-13 2009-09-23 Astrazeneca Ab 3 - (2r - tetrahidrofuril - metil) - 2 - tioxantina. composiciones farmaceuticas.
US20090054468A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
JP5757604B2 (ja) 2010-02-05 2015-07-29 ヒガシマル醤油株式会社 ミエロペルオキシダーゼ阻害剤
US9616063B2 (en) 2014-12-01 2017-04-11 Astrazeneca Ab 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase
US11241406B2 (en) 2015-08-28 2022-02-08 Nature's Sunshine Products, Inc. Compositions and methods for acutley raising nitric oxide levels
MA49618A (fr) 2017-07-17 2020-05-27 Astrazeneca Ab Inhibiteurs de la mpo destinés à être utilisés en médecine

Also Published As

Publication number Publication date
US20220160715A1 (en) 2022-05-26
MA49618A (fr) 2020-05-27
US20200206226A1 (en) 2020-07-02
AU2018304508A1 (en) 2020-02-27
CN110891572A (zh) 2020-03-17
KR20200029513A (ko) 2020-03-18
SG11202000086PA (en) 2020-02-27
EP3654983B1 (en) 2023-08-30
JP7220193B2 (ja) 2023-02-09
EP3654983A1 (en) 2020-05-27
NZ761505A (en) 2023-09-29
IL272043B (en) 2022-09-01
US11246870B2 (en) 2022-02-15
AU2018304508B2 (en) 2021-06-10
CA3068910A1 (en) 2019-01-24
CN110891572B (zh) 2023-08-15
JP2020527137A (ja) 2020-09-03
US11738027B2 (en) 2023-08-29
ZA202000904B (en) 2023-04-26
WO2019016074A1 (en) 2019-01-24
BR112019026270A2 (pt) 2020-06-30
IL272043A (en) 2020-03-31
ES2963315T3 (es) 2024-03-26

Similar Documents

Publication Publication Date Title
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201790413A1 (ru) Антитела против tigit
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
EA201691582A1 (ru) Новые фармацевтические препараты
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
EA201791095A1 (ru) Способ лечения рака
EA201791736A1 (ru) Комбинированная терапия для лечения рака
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
EA201890567A1 (ru) Способ лечения рака
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201790529A1 (ru) Новые антитела против mfi2 и способы их применения
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
MY192385A (en) Methods of treating acute kidney injury
EA201792610A1 (ru) Способ лечения неврологического заболевания
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MA40607B1 (fr) Traitements médicaux à base d'anamoréline
EA201892631A1 (ru) Дигидротестостерон и производные и промоторы дигидротестостерона в лечении рака